Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma

This study is testing a multi-targeted CAR-T cell therapy for people with B-cell lymphoma (a type of blood cancer) that has returned or stopped responding to standard treatments. This therapy engineers the patient's own immune cells to attack cancer cells that carry certain proteins (CD19, CD20, and/or CD22). **You may be eligible if...** - You are aged 2 to 75 years old - You have confirmed B-cell lymphoma that has relapsed or not responded after at least two prior treatment regimens - Your tumor tests positive for at least one of CD19, CD20, or CD22 - You are in reasonably good physical condition - You have at least one measurable area of cancer - Your heart, lungs, liver, and kidneys are working adequately **You may NOT be eligible if...** - You have another active cancer (other than cured cancers or those clear for 3+ years) - You recently took steroids or immune-suppressing drugs that could affect the cell therapy - You have active hepatitis B, C, HIV, or syphilis - You have significant uncontrolled heart problems (e.g., recent heart attack, very low pumping function) - You are pregnant or breastfeeding - You have an active autoimmune disease requiring immune suppression Talk to your doctor to see if this trial is right for you.